Chemistry:Ratutrelvir
From HandWiki
Ratutrelvir is an investigational new drug that is being evaluated by Traws Pharma[1] for the treatment of COVID-19 infections.[2][3] It is a 3C-like protease inhibitor.[3][4]
Clinical trials
Ratutrelvir is currently in a phase 2 clinical trial to test the effectiveness and safety of the drug in patients with COVID-19[5] and a preliminary analysis of the results has been released.[6]
References
- ↑ Rogovoy B, Kysil V, Berishvili V, Pauza CD, Zapata JC, Moreno SM, Li H, Orry A, Lam PC, Abagyan R, Savchuk N, "Compounds for treatment a coronavirus infection", WO patent 2023245162, published 2023-12-21, assigned to Trawsfynydd Therapeutics Inc.
- ↑ "International Nonproprietary Names for Pharmaceutical Substances (INN) Recommended INN: List 94". WHO Drug Information (World Health Organization) 39 (3): 809–1060 (976). 2025. https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/rl94.pdf?sfvrsn=e056a2a5_3&download=true.
- ↑ 3.0 3.1 "Travatrelvir - Traws Pharma". AdisInsight. Springer Nature Switzerland AG. https://adisinsight.springer.com/drugs/800076963.
- ↑ "Ratutrelvir | Ligand page". IUPHAR/BPS Guide to PHARMACOLOGY. https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13737.
- ↑ Early-stage Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to Moderate COVID-19. U.S. National Library of Medicine. 17 January 2026. Clinical trial record for NCT07157007. https://clinicaltrials.gov/study/NCT07157007. Retrieved 5 July 2026.
- ↑ ((Contagion Editorial Team)) (8 July 2026). "Traws Pharma Reports Differentiated COVID-19 and Influenza Antiviral Progress" (in en). Contagion Live. https://www.contagionlive.com/view/traws-pharma-reports-differentiated-covid-19-and-influenza-antiviral-progress.
 |  |
